These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 17910106)

  • 1. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli.
    Sorlózano A; Gutiérrez J; Romero JM; de Dios Luna J; Damas M; Piédrola G
    J Basic Microbiol; 2007 Oct; 47(5):413-6. PubMed ID: 17910106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of beta-lactam and non-beta-lactam antibiotics in extended-spectrum beta-lactamase-producing clinical isolates of Escherichia coli.
    Puerto AS; Fernández JG; del Castillo Jde D; Pino MJ; Angulo GP
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):135-9. PubMed ID: 16406187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli.
    Rodriguez-Villalobos H; Malaviolle V; Frankard J; de Mendonça R; Nonhoff C; Struelens MJ
    J Antimicrob Chemother; 2006 Apr; 57(4):771-4. PubMed ID: 16501056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
    Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
    Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Bishara J; Livne G; Ashkenazi S; Levy I; Pitlik S; Ofir O; Lev B; Samra Z
    Isr Med Assoc J; 2005 May; 7(5):298-301. PubMed ID: 15909461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance of strains producing extended-spectrum beta-lactamases and genotype distribution in China.
    Yu Y; Ji S; Chen Y; Zhou W; Wei Z; Li L; Ma Y
    J Infect; 2007 Jan; 54(1):53-7. PubMed ID: 16533535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalent phenotypes and antibiotic resistance in Escherichia coli and Klebsiella pneumoniae at an Indian tertiary care hospital: plasmid-mediated cefoxitin resistance.
    Shahid M; Malik A; Akram M; Agrawal LM; Khan AU; Agrawal M
    Int J Infect Dis; 2008 May; 12(3):256-64. PubMed ID: 17981482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiological and antibiotic resistant study on extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Zhejiang Province.
    Yu Y; Zhou W; Chen Y; Ding Y; Ma Y
    Chin Med J (Engl); 2002 Oct; 115(10):1479-82. PubMed ID: 12490091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First national surveillance of susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel.
    Colodner R; Samra Z; Keller N; Sprecher H; Block C; Peled N; Lazarovitch T; Bardenstein R; Schwartz-Harari O; Carmeli Y;
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):201-5. PubMed ID: 17258084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
    Zhanel GG; Baudry PJ; Tailor F; Cox L; Hoban DJ; Karlowsky JA
    J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.
    Morosini MI; García-Castillo M; Coque TM; Valverde A; Novais A; Loza E; Baquero F; Cantón R
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2695-9. PubMed ID: 16870760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Patterns of susceptibility to antibiotics of Enterobacteriaceae causing intra-abdominal infection in Spain: SMART 2003 study outcomes].
    Baquero F; Cercenado E; Cisterna R; de la Rosa M; García-Rodríguez JA; Gobernado M; Pérez JL; Manchado P; Martín R; Pascual A; Picazo J; Prats G; Rubio C; Snyder TA; Sanz-Rodríguez C
    Rev Esp Quimioter; 2006 Mar; 19(1):51-9. PubMed ID: 16688292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009).
    Hawser SP; Bouchillon SK; Lascols C; Hackel M; Hoban DJ; Badal RE; Cantón R
    Clin Microbiol Infect; 2012 Mar; 18(3):253-9. PubMed ID: 21635662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of antimicrobial agents against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon.
    Samaha-Kfoury JN; Kanj SS; Araj GF
    Am J Infect Control; 2005 Apr; 33(3):134-6. PubMed ID: 15798666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of co-resistance in CTX-M-producing Escherichia coli to non-beta-lactam antibiotics, with the exceptions of amikacin, nitrofurantoin, colistin, tigecycline, and fosfomycin, in a county of Sweden.
    Östholm Balkhed Å; Tärnberg M; Monstein HJ; Hällgren A; Hanberger H; Nilsson LE
    Scand J Infect Dis; 2013 Apr; 45(4):271-8. PubMed ID: 23113731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bactericidal activity of oral beta-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-spectrum beta-lactamases.
    Bedenic B; Vranes J; Suto S; Zagar Z
    Int J Antimicrob Agents; 2005 Jun; 25(6):479-87. PubMed ID: 15894465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Investigation of the frequency of extended spectrum beta-lactamases and antibiotic resistance in clinical isolates of Escherichia coli and Klebsiella sp].
    Ekşi F; Ozer G; Balci I
    Mikrobiyol Bul; 2007 Jul; 41(3):447-52. PubMed ID: 17933257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of ertapenem, ciprofloxacin, ceftriaxone, piperacillin-tazobactam, and ampicillin-sulbactam against 12 common clinical isolates of community-acquired bacteremia.
    Hwang KP; Tang YF; Shen YH
    J Microbiol Immunol Infect; 2009 Oct; 42(5):433-8. PubMed ID: 20182674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.